Quantum Biopharma (QNTM) Competitors $4.54 -0.05 (-1.09%) Closing price 03/12/2025 04:00 PM EasternExtended Trading$4.65 +0.11 (+2.42%) As of 03/12/2025 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends QNTM vs. GBIO, ESLA, PLUR, ATHE, SNYR, CELU, INKT, MRNS, IRD, and CALCShould you be buying Quantum Biopharma stock or one of its competitors? The main competitors of Quantum Biopharma include Generation Bio (GBIO), Estrella Immunopharma (ESLA), Pluri (PLUR), Alterity Therapeutics (ATHE), Synergy CHC Corp. (Uplisting) (SNYR), Celularity (CELU), MiNK Therapeutics (INKT), Marinus Pharmaceuticals (MRNS), Opus Genetics (IRD), and CalciMedica (CALC). These companies are all part of the "pharmaceutical products" industry. Quantum Biopharma vs. Generation Bio Estrella Immunopharma Pluri Alterity Therapeutics Synergy CHC Corp. (Uplisting) Celularity MiNK Therapeutics Marinus Pharmaceuticals Opus Genetics CalciMedica Generation Bio (NASDAQ:GBIO) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk, analyst recommendations and community ranking. Does the MarketBeat Community believe in GBIO or QNTM? Generation Bio received 43 more outperform votes than Quantum Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformGeneration BioOutperform Votes4370.49% Underperform Votes1829.51% Quantum BiopharmaN/AN/A Do insiders & institutionals have more ownership in GBIO or QNTM? 95.2% of Generation Bio shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 21.1% of Generation Bio shares are owned by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is GBIO or QNTM more profitable? Quantum Biopharma has a net margin of 0.00% compared to Generation Bio's net margin of -782.86%. Quantum Biopharma's return on equity of -84.21% beat Generation Bio's return on equity.Company Net Margins Return on Equity Return on Assets Generation Bio-782.86% -104.85% -49.54% Quantum Biopharma N/A -84.21%-62.63% Do analysts prefer GBIO or QNTM? Generation Bio presently has a consensus price target of $6.50, indicating a potential upside of 1,138.10%. Given Generation Bio's stronger consensus rating and higher possible upside, analysts plainly believe Generation Bio is more favorable than Quantum Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Generation Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Quantum Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, GBIO or QNTM? Generation Bio has a beta of 2.72, indicating that its share price is 172% more volatile than the S&P 500. Comparatively, Quantum Biopharma has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500. Does the media prefer GBIO or QNTM? In the previous week, Generation Bio and Generation Bio both had 1 articles in the media. Generation Bio's average media sentiment score of 1.89 beat Quantum Biopharma's score of 0.94 indicating that Generation Bio is being referred to more favorably in the media. Company Overall Sentiment Generation Bio Very Positive Quantum Biopharma Positive Which has better valuation & earnings, GBIO or QNTM? Quantum Biopharma has lower revenue, but higher earnings than Generation Bio. Quantum Biopharma is trading at a lower price-to-earnings ratio than Generation Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeneration Bio$18.58M1.89-$126.61M-$2.19-0.24Quantum BiopharmaN/AN/A-$17.90M-$15.41-0.29 SummaryGeneration Bio beats Quantum Biopharma on 12 of the 15 factors compared between the two stocks. Remove Ads Get Quantum Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for QNTM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QNTM vs. The Competition Export to ExcelMetricQuantum BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.71M$6.94B$5.64B$8.08BDividend YieldN/A2.72%4.89%4.04%P/E Ratio-0.296.1223.7318.99Price / SalesN/A226.08381.75120.64Price / CashN/A65.6738.0534.64Price / Book0.216.656.904.26Net Income-$17.90M$139.34M$3.18B$247.00M7 Day Performance0.89%-0.50%6.75%-1.60%1 Month Performance-57.37%-7.34%0.16%-9.68%1 Year PerformanceN/A-4.34%13.62%1.96% Quantum Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QNTMQuantum BiopharmaN/A$4.54-1.1%N/AN/A$8.71MN/A-0.29N/AGBIOGeneration Bio3.3663 of 5 stars$0.50-7.0%$6.50+1,213.1%-83.1%$33.06M$18.58M-0.23150Positive NewsESLAEstrella Immunopharma2.0629 of 5 stars$0.90-8.9%$16.00+1,677.8%-14.3%$32.56MN/A-3.46N/AShort Interest ↑Positive NewsPLURPluri0.8006 of 5 stars$4.62-2.1%N/A-39.4%$32.33M$678,000.00-0.82150Short Interest ↓ATHEAlterity Therapeutics2.671 of 5 stars$3.63-2.4%$12.00+230.6%+130.7%$32.19MN/A0.0010SNYRSynergy CHC Corp. (Uplisting)3.2648 of 5 stars$3.60-0.8%$10.00+177.8%N/A$31.33M$26.01M0.0040Positive NewsCELUCelularity0.6397 of 5 stars$1.31+6.5%N/A-73.4%$31.19M$48.20M0.00220Short Interest ↑Gap DownINKTMiNK Therapeutics3.0448 of 5 stars$7.66-6.6%$37.50+389.6%-12.5%$30.36MN/A-1.9630Upcoming EarningsMRNSMarinus Pharmaceuticals4.1232 of 5 stars$0.55-0.2%$4.79+771.6%-94.1%$30.32M$30.99M-0.22110Analyst ForecastIRDOpus Genetics2.6809 of 5 stars$0.93-6.9%$8.00+760.3%N/A$29.36M$8.38M-0.8514Upcoming EarningsGap UpCALCCalciMedica2.327 of 5 stars$2.17-3.1%$18.00+729.5%-57.3%$29.26MN/A-2.0130Gap Up Remove Ads Related Companies and Tools Related Companies Generation Bio Alternatives Estrella Immunopharma Alternatives Pluri Alternatives Alterity Therapeutics Alternatives Synergy CHC Corp. (Uplisting) Alternatives Celularity Alternatives MiNK Therapeutics Alternatives Marinus Pharmaceuticals Alternatives Opus Genetics Alternatives CalciMedica Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QNTM) was last updated on 3/13/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quantum Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quantum Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QNTM Stock Alerts